Transgene - New CEO to Catalyse Key Assets (Sponsored Research, TP EUR 3.20, 11 pgs)
Today, Transgene announced that CEO Brahim will retire and current Chairman, Dr. Riva, will take on the role, effective on Jun 1st, 2023. In our view, Dr. Riva is well suited for the position, bringing 30+ years of experience, including the launch of advanced therapies such as Yescarta, and will help to facilitate the development of the two lead assets, TG4050 and TG4001. Positive interim data for TG4050 in advanced H&N cancer was recently reported. With the median follow-up of 9.2mths, no relapses were observed in the treatment arm (N=16) compared to a 12.5% relapse rate in the control arm (N=16). Data confirmed that ‘4050 can elicit responses even in pts with poor systemic immunity, where immune checkpoint inhibitors have shown limited efficacy. Final results are expected in mid-24 & a potentially pivotal P2 will start in H223.For access to the full note, please contact Naresh Chouhan ( )
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.